These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 15550578

  • 1. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
    Tobias JS.
    Ann Oncol; 2004 Dec; 15(12):1738-47. PubMed ID: 15550578
    [Abstract] [Full Text] [Related]

  • 2. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW, Henderson IC.
    Breast Cancer Res Treat; 2003 Dec; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [Abstract] [Full Text] [Related]

  • 3. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    Buzdar AU, ATAC trialists' group.
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
    [Abstract] [Full Text] [Related]

  • 4. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS, Forbes JF.
    Breast Cancer Res Treat; 2003 Sep; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [Abstract] [Full Text] [Related]

  • 5. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [Abstract] [Full Text] [Related]

  • 6. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU, Cuzick J.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [Abstract] [Full Text] [Related]

  • 7. Role of anastrozole in adjuvant therapy for postmenopausal patients.
    Buzdar AU.
    Semin Oncol; 2003 Oct 01; 30(5 Suppl 16):21-9. PubMed ID: 14613023
    [Abstract] [Full Text] [Related]

  • 8. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M.
    Clin Ther; 2007 Aug 01; 29(8):1535-47. PubMed ID: 17919537
    [Abstract] [Full Text] [Related]

  • 9. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT, Robert NJ.
    MedGenMed; 2005 Aug 24; 7(3):20. PubMed ID: 16369246
    [Abstract] [Full Text] [Related]

  • 10. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
    Buzdar AU.
    Clin Cancer Res; 2004 Jan 01; 10(1 Pt 2):355S-61S. PubMed ID: 14734491
    [Abstract] [Full Text] [Related]

  • 11. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ.
    Oncology; 2005 Jan 01; 69(1):1-9. PubMed ID: 16088229
    [Abstract] [Full Text] [Related]

  • 12. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS.
    Ann Oncol; 2008 Jan 01; 19(1):16-27. PubMed ID: 17693420
    [Abstract] [Full Text] [Related]

  • 13. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU.
    Oncologist; 2003 Jan 01; 8(4):335-41. PubMed ID: 12897330
    [Abstract] [Full Text] [Related]

  • 14. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J, ABCSG and the GABG.
    Lancet; 2003 Jan 01; 366(9484):455-62. PubMed ID: 16084253
    [Abstract] [Full Text] [Related]

  • 15. Anastrozole.
    Cuzick J.
    Drugs Today (Barc); 2005 Apr 01; 41(4):227-39. PubMed ID: 16034487
    [Abstract] [Full Text] [Related]

  • 16. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A.
    Breast Cancer Res Treat; 2004 Jun 01; 85(3):247-54. PubMed ID: 15111763
    [Abstract] [Full Text] [Related]

  • 17. Focus on anastrozole and breast cancer.
    Mokbel K.
    Curr Med Res Opin; 2003 Jun 01; 19(8):683-8. PubMed ID: 14687437
    [Abstract] [Full Text] [Related]

  • 18. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE.
    Am J Clin Oncol; 2003 Aug 01; 26(4):S27-33. PubMed ID: 12902874
    [Abstract] [Full Text] [Related]

  • 19. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
    Nabholtz JM.
    Am J Hosp Palliat Care; 2004 Aug 01; 21(6):457-65. PubMed ID: 15612238
    [Abstract] [Full Text] [Related]

  • 20. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C, Keam SJ.
    Pharmacoeconomics; 2006 Aug 01; 24(5):495-517. PubMed ID: 16706574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.